Agricultural and household organophosphorus (OP) pesticides inhibit acetylcholinesterase (AchE), resulting in increased acetylcholine (Ach) in the central nervous system. In adults, acute and prolonged exposure to high doses of AChE inhibitors causes severe, clinically apparent symptoms, followed by lasting memory impairments and cognitive dysfunction. The neurotoxicity of repeated environmental exposure to lower, subclinical doses of OP pesticides in adults is not as well studied. However, repeated exposure to acetylcholinesterase inhibitors such as chlorpyrifos (CPF), pyridostigmine, and sarin nerve agent have been epidemiologically linked to delayed onset symptoms in Gulf War Illness, and may be relevant to environmental exposure in farm workers among others. We treated adult mice with a subclinical dose (5 mg/kg) of CPF for 5 consecutive days, and investigated hippocampal synaptic transmission and spine density early (2-7 days) and late (3 months) following CPF administration. No signs of cholinergic toxicity were observed at any time during or after treatment. At 2-7 days following the last injection, we found increased synaptic transmission in the CA3-CA1 region of the hippocampus of CPF treated mice compared to controls. In contrast, at 3 months following CPF administration, we observed a 50% reduction in synaptic transmission likely due to a corresponding 50% decrease in CA1 pyramidal neuron synaptic spine density. This study is the first to identify a biphasic progression of synaptic deficits following repeated OP exposure, and suggests that even in the absence of acute cholinergic toxicity, repeated exposure to CPF causes delayed, persistent damage to the adult brain in vivo.
INTRODUCTION
Organophosphorus (OP) pesticides have broad household, agricultural, and military applications worldwide. These compounds inhibit acetylcholinesterase (AchE), and can be acutely toxic to humans at high doses (Kaplan et al., 1993; Dassanayake et al., 2008; Eaton et al., 2008; Jurewicz and Hanke, 2008) . OP poisoning results in a biphasic progression of symptoms beginning with nausea, headache, fatigue, and seizures (Brown and Brix, 1998; Aardema et al., 2008) . Exposure to moderate and high levels of OP pesticides is often followed by persistent, delayed cognitive deficits (Kaplan et al., 1993; Dassanayake et al., 2008) and sensory (Kaplan et al., 1993; Murata et al., 1997) and motor neuropathies (Lotti and Moretto, 2005) . Specifically, the OP pesticide chlorpyrifos (CPF) has been shown to cause impairments in short-term memory and cognition in adults (Kaplan et al., 1993) and in mature rodents (Bushnell et al., 1994; Cohn and MacPhail, 1997; Sanchez-Santed et al., 2004; Canadas et al., 2005) .
While exposure to low levels of OP pesticides does not inhibit AchE to the same extent or result in the same types of severe, acute clinical symptoms as exposure to high doses, epidemiologic evidence suggests that persistent, subclinical exposure to OP pesticides also can lead to longterm neurological impairment in adults (Jamal et al., 2002a; Jamal et al., 2002b) , and in children (Rauh et al., 2006; Jurewicz and Hanke, 2008) . Long-term, low-dose OP exposure has been implicated as a risk factor for Parkinson's disease (Manthripragada et al., 2010) , and for amyotrophic lateral sclerosis (ALS) (Morahan et al., 2007) . Cognitive (Dassanayake et al., 2009) and sensory (Pilkington et al., 2001; Jamal et al., 2002b) deficits have also been reported following occupational exposure to OP pesticides. Furthermore, combined exposure of U.S.
troops to subclinical levels of OP pesticides and to more potent, irreversible OP nerve agents such as sarin and soman, is hypothesized to underlie many neurological symptoms and susceptibilities of Gulf War Illness (GWI) (Haley and Kurt, 1997; Jamal, 1998; Mahoney, 2001; Haley, 2003a; Golomb, 2008) .
Environmental exposure to CPF is also a concern for the general population. In 1995, it was estimated that up to 82% of adults in the U.S. contained detectable levels of CPF metabolites in their urine (Hill et al., 1995) . Though the U.S. restricted CPF from home use in 2002 due to its neurotoxic effects on childhood development (U.S. EPA Administrator Announcement, 2000) , it remains a ubiquitous environmental neurotoxin, and is still widely used in golf course maintenance and in agriculture (Eaton et al., 2008) .
While the peripheral, sensory, and autonomic mechanisms of acute, high-dose OP poisoning are well-studied in adults, the physiological mechanisms of CNS dysfunction arising from repeated exposure to subclinical doses of OP in vivo are not. Behavioral studies in rodents have identified hippocampus-dependent learning and memory as a target for the neurotoxic effects of repeated, subclinical CPF exposure (Prendergast et al., 1998; Terry et al., 2003) , but the underlying synaptic mechanisms are unclear. The purpose of this study is to identify the early and delayed effects of repeated, subclinical OP exposure on the adult mouse hippocampus, including changes in synaptic transmission, synaptic spines, and neuronal numbers which may cause deficits in hippocampus-dependent cognitive behaviors. Cowan et al. (2001) . Adult male mice 10-12 weeks old (C57Bl/6J, 25-30 g, Jackson Laboratories, Bar Harbor, ME) were injected (s.c.) with either 5 mg/kg CPF dissolved in DMSO or with DMSO alone (vehicle control) for 5 consecutive days at a concentration of 1 mg/ml. This dose was chosen since it has been previously shown to cause < 10% whole-brain AchE inhibition following a single dose (Cowan et al., 2001) , and is within range of the threshold (2 mg/kg) for erythrocyte AChE inhibition in humans (Kisicki et al., 1999) . For studies investigating the early effects of CPF exposure, testing began 2 days following the last injection; for studies investigating the delayed effects of CPF exposure, testing began 3 months following the last injection. All experimental procedures were approved by the Institutional Animal Care and Use Committee of the UT Southwestern Medical Center, and are in accordance with NIH policy on the care and use of laboratory animals.
MATERIALS AND METHODS

Animals and Drugs. Treatment of mice with CPF was modified from
AchE Activity and Protein Quantification Assays. Mice were euthanized with CO 2 gas and their brains harvested at 3 hours and 6 hours following the first injection, and at 3 hours and 24 hours following the last injection. Brains were isolated, bisected, and snap frozen on dry ice then stored at -80 o C. The hippocampus was isolated from one hemisphere of each brain, diluted 1:40 (w/v) in 0.1 M phosphate-buffered saline (PBS), and homogenized using an ultrasonic processor (Cole Parmer, Vernon Hills, IL). Lysates were centrifuged and the supernatant tested for AChE activity within 24 hours of tissue harvesting using the DACE-100 QuantiChrom Acetylcholinesterase Assay Kit (BioAssay Systems, Hayward, CA) according to the manufacturer's protocol. AChE activity was then normalized to total protein concentration for each sample using the DC Protein Assay kit (Bio-Rad, Hercules, CA). AChE and protein assays were carried out in triplicate in 96-well plates using a Synergy HT Multi-Mode Microplate Reader (Bio-Tek, Winooski, VT).
Electrophysiology. Mice were briefly anesthetized with the inhalation anesthetic isoflurane (Baxter Healthcare Corporation, Deerfield, IL), and rapidly decapitated for extracellular recordings. For whole-cell patch clamp recordings, mice were deeply anesthetized with 400 mg/kg (i.p.) chloral hydrate (Sigma, St. Louis, MO) then vascularly perfused through the heart with ice-cold artificial cerebrospinal fluid (ACSF). Brains were quickly removed and placed in ice-cold modified ACSF. Transverse hippocampal slices (300-350 µm for whole-cell recordings and 350-400 µm for extracellular recordings) were made using a vibrating microtome (Vibratome, Bannockburn, IL). Slices were allowed to recover at 33 o C for 30 minutes in normal ACSF and slowly cooled to room temperature over a 45 minute period prior to recording.
Modified ACSF contained (in mM): 75 sucrose, 87 NaCl, 3 KCl, 1.25 NaH 2 PO 4 , 7 MgSO 4 , 26 NaHCO 3 , 20 dextrose, and 0.5 CaCl 2 . ACSF contained (in mM): 126 NaCl, 3 KCl, 1.25 NaH 2 PO 4 , 1 MgSO 4 , 26 NaHCO 3 , 10 dextrose, and 2 CaCl 2 . All solutions were pH 7.4 and saturated with 95% O 2 / 5% CO 2 .
All recordings were performed at 33 ± 0.5 o C, and all data were collected using Clampex (pClamp software suite version 10.2, Molecular Devices, Sunnyvale, CA). Whole-cell and extracellular recordings were filtered at 1-3 kHz and digitized at 10 kHz. CA3-CA1 synapses were stimulated by a bipolar nickel dichromate stimulating electrode, and field excitatory postsynaptic potentials (fEPSPs) were recorded using glass pipette electrodes (3-5 MΩ) filled with ACSF and placed 400-500 µm apart, laterally, in the stratum radiatum. The distance between the recording electrode and the stimulating electrode was kept constant within these bounds using a SZX7 dissecting microscope (Olympus, Center Valley, PA) at 5X magnification.
Sample size represents number of mice tested with only one slice/mouse included. Response size was determined by fitting a straight line to the initial slope (10-40 %) of the fEPSP using automated analysis in Clampfit (pClamp software suite version 10.2, Molecular Devices, Sunnyvale, CA). For studies of long-term potentiation (LTP), stimulus intensity was set to generate approximately 50% of the maximum fEPSP, as determined by the input/output (I/O) curve. I/O curves were performed in each slice immediately preceding each LTP experiment, and stimulus intensity remained unchanged for the duration of the LTP experiment.
Whole-cell patch clamp recordings were performed at 33 ± 0.5 o C in the presence of 2 µM TTX to block evoked transmission and 100 µM picrotoxin to block fast inhibitory transmission.
Neurons were visualized under DIC microscopy using an AxioExminerD1 microscope (Zeiss, Thornwood, NY). Spontaneous miniature excitatory postsynaptic currents (mEPSCs) were recorded from a holding potential of -65 mV for 2-3 minute intervals starting 3-5 minutes after break-in using glass pipette electrodes 4-6 MΩ. Internal solution contained (in mM): 117 CsMeSO 3 , 15 CsCl, 8 NaCl, 10 TEA, 3 QX-314, 0.2 EGTA, 10 HEPES, 2 ATP, 0.3 GTP and adjusted to pH 7.3 and 290 mOsm. Only experiments with a high seal resistance (>3 GΩ) were analyzed, and were rejected if the series or input resistance changed by more than 25% during the recording. Sample size represents no more than 1 neuron/slice and no more than 4 slices/mouse. Clampfit was used to measure peak amplitude and rise time (10-90%) of mEPSCs using automated analysis. The decay constant (τ) of mEPSCs was calculated from single exponential fits using the Levenberg-Marquardt least squares algorithm. Sample size represents one neuron per slice, though more than one slice was used from each mouse. All statistically length, 2) Segment must cross the midpoint of the defined region, 3) Segment cannot branch along the measured length, and 4) No interfering crossing of other branches that would interfere with spine counting. Two segments were chosen from each distance in both the apical and basilar dendritic arbors. Segments from the same region in the same neuron were averaged together prior to statistical analysis.
Stereology was performed on 4 mice per treatment group. Mice were transcardially perfused with 0.1 M PBS and 4% paraformaldehyde (PFA). Brains were then cryoprotected in 30% sucrose in PBS before collecting 30 µm coronal sections in 12 series using a freezing sliding microtome. In order to quantify the number of neurons in CA1 and CA3, we employed a rigorous stereological approach using the optical fractionator method using StereoInvestigator software (MicroBrightField Bioscience, Williston, VT). Neurons were identified by staining sections using 4′,6-Diamidino-2-phenylindole dihydrochloride (DAPI; Sigma D9542). For counting both CA1 and CA3 neurons, every 12th section (in other words, a section sampling fraction of 1/12) was examined through the entire rostrocaudal extent of the hippocampus using a random series start. For area CA1, the step size across sections was 100 µm x 100 µm, and the dissector dimensions were 15 µm x 15 µm, with a height of 12 µm. For CA3, the step size was 140 µm x 140 µm, and the dissector dimensions were 20 µm x 20 µm, with a height of 12 µm.
These sampling parameters yielded a coefficient of error of less than 10%. All slides were coded and counted by an observer blind to the treatment condition.
Statistics. All statistical analysis was performed using SigmaPlot (version 11.0, Systat Software, Chicago, IL) and Statistica (version 5.5, StatSoft, Inc., Tulsa, OK) software packages. Statistics were performed using either a Student's t-test, two-way ANOVA, or two-way repeated measures Compounds. CPF (diethoxy-sulfanylidene-(3,5,6-trichloropyridin-2-yl)oxy-λ 5 -phosphane) was 
RESULTS
Five-day treatment with 5 mg/kg CPF does not induce acute cholinergic toxicity. Prolonged and
acute exposure to high doses of OP compounds, such as CPF, elicit well-defined signs of acute cholinergic toxicity primarily due to overactivation of acetylcholine receptors (AchRs) in the peripheral and autonomic nervous systems (Moser, 1995; Aardema et al., 2008) . The present study focuses on the long-term effects of repeated exposure to a subclinical dose of CPF that does not elicit any signs of overt cholinergic toxicity (Cowan et al., 2001) . To ensure that mice received subclinical exposure to CPF, signs of OP poisoning were qualitatively observed throughout the treatment period, including weight loss, which is associated with CPF poisoning (Moser, 1995) . No signs of cholinergic toxicity were observed in healthy mice (25-30 g), and no change in weight ( Figure 1A ) was observed between days 1 and 5 of treatment in either CPF or control groups (two-way repeated measures ANOVA. Treatment: P = 0.912; Day: P < 0.001; Treatment x Day Interaction: P = 0.572; N = 20 per group).
We also measured AChE activity in the hippocampus at four time points during and after the CPF treatment period ( Figure 1B ), and found a main effect of treatment on AChE activity (Twoway ANOVA. Treatment: P < 0.001; Day: P = 0.613; Treatment x Day Interaction P = 0.131; N = 12 per group). We found no significant inhibition of AChE with CPF at 3 hours (2.97 % compared to vehicle; P = 0.822) or at 6 hours (18.34 % compared to vehicle; P = 0.162) following the first injection in CPF-treated mice compared to vehicle controls, confirming that 5 mg/kg is a low dose of CPF, and does not cause significant inhibition of AChE activity after one injection. However, repeated administration of this low dose of CPF does result in "build-up" of following the last injection of the 5-day treatment period. This additive effect of AChE inhibition with repeated CPF exposure in mice is consistent with a previous report of progressive build-up of CPF metabolites and AChE inhibition following 10-day exposure to 3 mg/kg and 10 mg/kg CPF s.c. over a 10-day treatment period in rats (Ellison et al., 2011) . Taken and in the maximum slope of the fEPSP at stimulus intensities above 3.0 mA (two-way repeated measures ANOVA. Treatment: P = 0.107; Intensity: P < 0.001; Treatment x Intensity Interaction: P < 0.001, N = 8 mice per group). At the maximum stimulus intensity applied, the mean fEPSP slope was 44% greater in CPF-treated mice compared to vehicle-treated mice (-0.33 ± 0.04 mV/ms for vehicle vs. -0.47 ± 0.04 mV/ms for CPF; Student's t-test, P < 0.036).
To determine whether this increase in synaptic transmission might be mediated by alterations in presynaptic release mechanisms, we looked for changes in the paired-pulse ratio (PPR) of fEPSPs as a measure of presynaptic function. In this experiment, two consecutive pulses of equal stimulus intensity, determined at 50-60% of the stimulus intensity needed to elicit maximal fEPSP magnitude, are applied at specific intervals ranging from 50-500 ms. As a general 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 principle, the ratio of the second pulse to that of the first is inversely related to the initial release probability of the presynaptic neuron (Manabe et al., 1993; Debanne et al., 1996; Dobrunz and Stevens, 1997; Dobrunz, 2002) . No difference in PPR ( Figure 2B ) was observed between CPFtreated and vehicle-treated mice at any interstimulus interval (two-way repeated measures ANOVA. Treatment: P = 0.117; Interstimulus Interval: P < 0.001; Treatment x Interval Interaction: P = 0.318; veh N = 8, CPF N = 9). These results indicate that the immediate increase in excitatory transmission with CPF treatment does not affect short-term plasticity, and is not likely mediated by a change in initial release probability.
Early effects of CPF treatment on long-term potentiation (LTP) were also analyzed in the first week following the last injection using a strong conditioning protocol (4, 1s, 100 Hz trains given at 0.1 Hz; Figure 2C ). Following a 20 minute baseline, fEPSP slope was measured at 0.1 Hz for 60 minutes post-tetanus. Both groups demonstrated reliable LTP, and when the magnitude of LTP was measured between 50 and 60 minutes post-tetanus, no difference in fEPSP slope was found between CPF-treated and control mice (163.93 ± 11.61 mV/ms for vehicle vs. 176.84 ± 18.67 mV/ms for CPF; Student's t-test, P = 0.577; veh N = 8, CPF N = 9). Thus, despite an increase in excitatory synaptic transmission, expression and maintenance of LTP were unaffected.
We also used Golgi staining and histology of 18 neurons from 3 mice per treatment group to determine whether changes in spine density could account for the early increase in hippocampal synaptic transmission in CPF-treated mice (Figure 3 ). CA1 neurons were chosen in Golgi stained hippocampal sections from either vehicle control ( Figure 3B ) or CPF-treated ( Figure 3C 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 spines/10µm for CPF; Student's t-test, P = 0.700). Next, we investigated distance-dependent changes in spine density along CA1 dendrites in CPF-treated and vehicle-treated mice. No difference in spine density was observed between CPF-treated and control mice with regard to branch order on apical segments ( Figure 3D ; Student's t-test, P > 0.05) or on basal segments ( Figure 3F ; Student's t-test, P > 0.05). At apical dendrites 270-310 µm from the soma, there was a small, but significant decrease in spine number in CPF-treated mice compared to vehicle controls ( Figure 3E ; 25.77 ± 0.518 spines/10µm for vehicle vs. 21.97 ± 1.13 spines/10µm for CPF; Student's t-test, P = 0.022), but at distances < 210 µm from the soma, no difference in spine number was observed ( Figure 3E ; Student's t-test, P> 0.05). In addition, no change in spine density, measured in 60 µm increments beginning 30 µm from the soma, was found on basal dendrites between mice treated with CPF and those treated with vehicle ( Figure 3G ; Student's ttest, P > 0.05). Therefore, CA1 spine number is not greatly affected at one week following CPF treatment.
Hippocampal synaptic transmission is severely impaired 3 months following CPF treatment. To determine the delayed effects of prolonged, low-dose exposure to CPF on hippocampal function, we compared I/O relationships of stimulus intensity to fEPSP slope in CPF-treated and control, vehicle-treated mice ( Figure 4A ). We found a large decrease in fEPSP slope at almost all stimulus intensities compared to control mice, indicating a delayed decrease in synaptic transmission following CPF treatment (Treatment: P < 0.001; Intensity: P < 0.001; Treatment x Stimulus Intensity Interaction: P < 0.001; veh N = 12, CPF N = 11). At the maximum stimulus intensity, mice receiving CPF injections exhibited a 52% reduction in mean fEPSP slope compared to mice receiving vehicle injections (-1.35 ± 0.10 mV/ms for vehicle vs. -0.70 ± 0.08 mV/ms for CPF; Student's t-test, P < 0.001). Thus, in striking contrast to our findings during the 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 first week following treatment in which the maximal fEPSP slope was increased in CPF-treated mice (Figure 2A ), we find a delayed, significant reduction in hippocampal synaptic transmission at 3 months following CPF treatment.
Such a dramatic decrease in synaptic transmission could be expected to impair hippocampal synaptic plasticity. Therefore, delayed effects of CPF treatment on short-and long-term plasticity were investigated. When PPR was compared between CPF-treated and vehicle-treated mice, we found no significant difference at any interstimulus interval 50-500 ms ( Figure 4B ; two-way repeated measures ANOVA; Treatment: P = 0.107; Interstimulus Interval: P < 0.001; Treatment x Interval Interaction: P = 0.306; N = 11 per group), suggesting that at our dose, CPF does not affect short-term plasticity, and by extrapolation, does not affect presynaptic function at CA3-CA1 synapses. Similarly, when we compared magnitude of LTP at 50-60 min following tetanic stimulation, no significant difference was observed between CPF-treated and vehicle-treated mice ( Figure 4C ; 140.92 ± 0.87 mV/ms for vehicle vs. 140.21 ± 0.48 mV/ms for CPF; Student's t-test, P = 0.475). The lack of deficits in short-term synaptic plasticity with CPF treatment suggests that synaptic changes in presynaptic function may not be responsible for the large reduction in excitatory transmission in mice receiving CPF injections.
Another potential cause for a decrease in fEPSP slope with CPF treatment is a change in the number of synapses or neurons in the CA3-CA1 region of treated mice. We first tested this hypothesis by measuring amplitude and frequency of spontaneous miniature excitatory currents (mEPSCs) from CA1 pyramidal neurons ( Figure 5 ). Whole-cell patch-clamp recordings (veh N = 28 neurons from 8 mice, CPF N = 21 neurons from 9 mice, no more than one neuron per slice)
were made from CA1 cell bodies in the stratum pyramidale (s.p.) in the presence of the Na 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 channel blocker TTX (2 µM) to block activity-dependent synaptic transmission and the GABA A receptor antagonist picrotoxin (100 µM) to block fast inhibitory transmission ( Figure 5A ). Mean suggest that the decrease in basal synaptic transmission in CPF-treated mice is primarily due to a decrease in either the number of CA3 synapses onto CA1 pyramidal neurons or to a decrease in CA3 or CA1 neuron number, though decreased input resistance may further impede the ability of CA1 neurons to respond to incoming stimuli in CPF-treated mice.
Spine number, but not neuron number is greatly decreased at 3 months following CPF treatment.
Prolonged, direct exposure of organotypic hippocampal slice cultures to CPF at 100 µM, but not 10 µM, has been shown to cause CA1 neuron loss (Terry et al., 2003) , and in utero repeated exposure of rats to low-dose CPF causes neuron loss in the cerebellum that persists into adulthood (Abou-Donia et al., 2006) . To determine whether repeated exposure of adult mice to 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 low doses of CPF in vivo results in neuronal loss sufficient to explain our observed decrease in synaptic transmission, we measured neuron number in the CA1 and CA3 regions of the entire hippocampus of 4 mice per treatment group using unbiased stereology. No difference in mean CA1 neuron number across the entire hippocampus was observed between CPF-treated and vehicle-treated mice ( Figure 6A , 145297 ± 5040 neurons/mouse for vehicle vs. 145938 ± 8719 neurons/mouse for CPF; Student's t-test, P = 0.951), nor was there a difference in CA3 neuron number ( Figure 6B , 121252 ± 12627 neurons/mouse for vehicle vs. 131698 ± 16443 neurons/mouse for CPF; Student's t-test, P = 0.632), indicating that low-dose CPF treatment does not cause a significant, lasting loss of neurons in the CA1 ( Figure 6C , vehicle-treated; Figure 6E , CPF-treated) or CA3 regions ( Figure 6D , vehicle-treated; Figure 6F , CPF-treated).
Next, we performed histological analysis on Golgi-stained hippocampal sections from vehicletreated ( Figure 7B ) and CPF-treated ( Figure 7C ) mice to determine if the late decrease in hippocampal synaptic transmission was due to a decrease in synaptic spine number. As described for early effects of CPF treatment, 18 neurons were analyzed/treatment group with one neuron analyzed/section, and six neurons analyzed/mouse. Interestingly, total spine density was reduced by 40% in CPF-treated mice compared to vehicle controls ( Figure 7A , 20.97 ± 0.74 spines/10µm for vehicle vs. 12.57 ± 0.77 spines/10µm for CPF; Student's t-test, P < 0.001), indicating loss of synaptic spines as the likely mechanism of the large reduction in CA3-CA1 synaptic transmission. The delayed decrease in spine density with CPF treatment was observed throughout the length of the apical dendrite, as measured in 60 µm increments beginning at 30 µm from the soma ( Figure 7D ; Student's t-test, P < 0.005). Similarly, the decrease in spine density was also significant along the entire basal dendrite, also measured in 60 µm increments beginning at 30 µm from the soma ( Figure 7F ; Student's t-test, P < 0.001). With regard to branch Figure 7E ; Student's t-test, P < 0.05), and at all branch points (1-5) of basal dendrites ( Figure 7G ; Student's t-test, P < 0.05). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
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DISCUSSION
Early versus delayed effects of repeated, subclinical CPF treatment.
This study is the first to report that repeated, subclinical doses of CPF result in a biphasic progression of hippocampal synaptic dysfunction in adult mice, with early effects being strikingly different than delayed effects. CA3-CA1 synaptic transmission was enhanced in CPF-treated mice compared to vehicletreated mice at the one-week time point. These results are consistent with studies on therapeutic AchE inhibitors showing improved hippocampal synaptic function and learning and memory in patients with Alzheimer's disease (Birks, 2006) . Conversely, at 3 months following the last injection, we have identified a dramatic decrease in the slope of fEPSPs in response to extracellular stimulation in CPF-treated mice compared to vehicle-treated controls. This is accompanied by a drastic decrease in the frequency of mEPSCs, slowing of mEPSC kinetics, and decreased input resistance of CA1 neurons in CPF-treated mice.
While our results are in line with reports of CPF-induced delayed cytotoxicity in vitro (Terry et al., 2003; Tan et al., 2009; Rush et al., 2010) , we did not observe any change in neuron number in either the CA3 or CA1 regions with treatment in vivo. However, we did observe a large, novel decrease in synaptic spine density across both basilar and apical dendrites of CA1 neurons, indicating that synaptic spine loss, rather than neuron loss is responsible for the decrease in basal hippocampal synaptic transmission at 3 months following CPF treatment.
Effects of route and dose on AChE inhibition.
The effects of CPF have been shown to be dependent on route of exposure (Marty et al., 2007; Carr and Nail, 2008; Smith et al., 2009 ), length of exposure (Marty et al., 2007) , dose (Baireddy et al., 2011), and vehicle (Marty et al., 2007; Carr and Nail, 2008; Smith et al., 2009 ). The 5 mg/kg dose of CPF used in this study does No signs of cholinergic toxicity were observed at any time during treatment, consistent with Ellison et al. (2011) who saw a similar lack of clinical symptoms in adult rats following a 10-day treatment period with 3 mg/kg and 10 mg/kg CPF s.c. Similarly, Middlemore-Risher et al. (2010) reported that no signs of cholinergic toxicity were elicited by 14-day treatment of adult rats with 18 mg/kg CPF despite a 63.3% reduction in AChE activity in hippocampus. Therefore this dose is higher than is likely to be found through dietary or environmental exposure, though still low enough not to elicit signs of cholinergic toxicity. It remains unclear whether this exposure is in any way comparable to that experienced by veterans suffering from GWI (Haley and Kurt, 1997; (Szabo et al., 2008; Penton et al., 2011) , and has been shown to lower the threshold for LTP induction at CA3-CA1 synapses (Fujii et al., 1999; 2000a; 2000b) , as does septal stimulation (Gu and Yakel, 2011) . mAChRs are slower-acting second messengercoupled receptors that enhance hippocampal excitatory transmission through modulation of Ca 2+ , 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 K + , and mixed ion currents (reviewed in Cobb and Davies, 2004) that are also capable of modulating glutamatergic CA3-CA1 synaptic plasticity (Gu and Yakel, 2011) . Given that our 5-day treatment protocol causes a build-up of AChE inhibition, the early increase in excitatory transmission in CPF-treated mice is likely due to increased activation of AChRs by moderate AChE inhibition. The delayed effects of AChE inhibition on synaptic spines and synaptic transmission remain a mystery that will require multiple future experimental approaches to delineate. signaling (Slotkin and Seidler, 2009) , and axonal transport (Terry et al., 2003; Terry et al., 2007) .
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Non-cholinergic effects
In the developing nervous system, CPF has been shown to impair axon growth in vitro (Howard et al., 2005; Yang et al., 2008; , while also stimulating dendritic growth (Howard et al.,
2005) through non-enzymatic mechanisms. Transient upregulation of neurotrophins, such as brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), have also been identified in young rats treated with subclinical doses of CPF (Betancourt et al., 2007) and in primary hippocampal neurons in vitro (Tan et al., 2009 ). However, the role of CPF on axonal and dendritic length, as well as neurotrophin signaling in mature rodents following CPF treatment in vivo is unknown.
Neurotrophin signaling may also contribute to the long-term deficits in hippocampal synaptic transmission and the decrease in spine number observed 3 months following repeated CPF administration. Transient upregulation of ERK signaling observed by Tan et al. (2009) 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 followed by a delayed, cytotoxic decrease in ERK phosphorylation after treatment. This may indicate a delayed downregulation of neurotrophin or glutamatergic NMDA receptor (NMDAR) signaling in CPF-treated mice. BDNF also modulates the frequency and late component of mEPSCs in hippocampal neurons through NMDARs (Madara and Levine, 2008), offering another potential mechanism by which synapse number and synaptic transmission are impaired at CA3-CA1 synapses at 3 months following CPF administration in vivo.
Clearly, the connection between CPF exposure and delayed decreases in synaptic spine density and synaptic transmission are ripe for future studies. Understanding the biochemical mechanisms of spine formation and maintenance and how these mechanisms are altered following CPF exposure will be critical to identifying potentially novel therapeutic targets for delayed effects of such exposures in humans.
CPF susceptibility, prevention, and treatment. The results of this study have potentially serious implications for public health, as the consequences of repeated subclinical exposure to OP pesticides has been shown to cause lasting deficits in cognitive performance in humans (Kaplan et al., 1993) and in rodents (Cohn and MacPhail, 1997 , Sanchez-Santed et al., 2004 , Canadas et al., 2005 . In addition, repeated exposure to low doses of CPF renders the hippocampus susceptible to subsequent "second hit" neurological and environmental insults, including additional doses of CPF and related compounds. In support of this, impairments in working memory were found to be more profound in mice receiving two injections of toxic, high-dose CPF 22 weeks apart, than with a single toxic dose of CPF (Sanchez-Santed et al., 2004; Canadas et al., 2005) , and heritable mutations in the paraoxonase1 (PON1) gene that is responsible for OP metabolism have been shown to further increase susceptibility to OP pesticides (Costa et al., 2003) . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 In humans, occupational exposure is one potential source of "second hit" toxicity. For example, agricultural workers and their families are exposed to higher doses of CPF and other OP compounds than the general population, and retain higher concentrations of metabolites in their urine (Coronado et al., 2006) . This prolonged daily exposure does not elicit acute symptoms of OP toxicity, yet is believed to be the cause of delayed COPIND (Jamal et al., 2002a) .
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Military personnel are at greater risk of CPF and OP-induced neurotoxicity since they may be exposed to subclinical levels of OP pesticides, irreversible OP nerve agents, and pyridostigmine bromide. Combined exposure to low levels of these compounds is thought to be a contributing factor in GWI (Haley and Kurt, 1997; Jamal, 1998; Mahoney, 2001; Haley, 2003a; Golomb, 2008) . Furthermore, the delayed reduction in synaptic transmission may lead to reduced hippocampal "reserve." With already weakened synaptic transmission, these veterans may experience earlier symptoms in neurodegenerative disorders such as Alzheimer's dementia or in response to traumatic brain injury. Similar delayed neurotoxic effects of CPF on other central neurons may underlie increased incidence of Amyotrophic Lateral Sclerosis (Haley, 2003b; Saeed et al., 2006) and Parkinson's disease (Kamel and Hoppin, 2004) in Gulf War veterans exposed to AChE inhibitors. In future studies, it will be of great interest to determine if substantia nigra or motor neurons are similarly affected by low-dose CPF exposure.
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http://toxsci.oxfordjournals.org/ Downloaded from Figure 7 . Spine density is dramatically decreased in CPF-treated mice compared to controls at 3 months following treatment. (A) Total spine density is decreased in CPF-treated mice compared to vehicle controls (*P < 0.001 compared to vehicle). 100X magnification of dendritic spines in Golgistained CA1 pyramidal neurons from vehicle-treated (B) and CPF-treated mice (C). Scale bars: 10 µm. The decrease in spine density of (D) apical dendrites (*P < 0.01 compared to vehicle) and (F) basilar dendrites in CPF-treated mice is not dependent on distance from soma (*P < 0.001 compared to vehicle). (E) The decrease in spine density of apical dendrites is significantly different than controls up to the third branch point (*P < 0.05 compared to vehicle). (G) The decrease in spine density of basilar dendrites in CPF-treated mice is not dependent on number branch points. For panels D-G, data represent means ± SEM. 123x149mm (300 x 300 DPI) 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
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